Table 6. Number and percentage of PwMS in each major disability category by DMD use and polypharmacy.
| Level of disability (PDDS) | ||||||
| Normal/some n (%) | Moderate n (%) | Major n (%) | Total n (%) | P | ||
| DMD use | Yes | 674 (61.6)* | 355 (32.4) | 66 (6.0)† | 1095 (100) | < 0.001 |
| No | 557 (49.2)† | 410 (36.2) | 166 (14.7)* | 1133 (100) | ||
| Total | 1231 (55.3) | 765 (34.3) | 232 (10.4) | 2228 (100) | ||
| Polypharmacy | Yes | 107 (31.6)† | 165 (48.7)* | 67 (19.8)* | 339 (100%) | < 0.001 |
| No | 1160 (59.2)* | 628 (32.0)† | 173 (8.8)† | 1961 (100%) | ||
| Total | 1267 (55.1) | 793 (34.5) | 240 (10.4) | 2300 (100) | ||
| Polypharmacy among subsample with DMD use | Yes | 48 (41.4) † | 56 (48.3)* | 12 (10.3)* | 116 (100.0) | < 0.001 |
| No | 393 (64.3)* | 185 (30.3) † | 33 (5.4) † | 611 (100.0) | ||
| Total | 441 (60.7) | 241 (33.1) | 45 (6.2) | 727 (100.0) | ||
| Polypharmacy among subsample without DMD use | Yes | 38 (24.7)† | 70 (45.5)* | 46 (29.9)* | 154 (100.0) | < 0.001 |
| No | 519 (53.0)* | 340 (34.7%)† | 120 (12.3%)† | 979 (100.0) | ||
| Total | 557 (49.2) | 410 (36.2) | 166 (14.7) | 1133 (100.0) | ||
DMD: disease-modifying drug; PDDS: patient-determined disease steps; PwMS: people with multiple sclerosis.
*
Bold faces denote significantly over-represented as determined by standardized adjusted residuals.
†
Denotes significantly under-represented as determined by standardized adjusted residuals.